Among the several goals of a high-throughput screening campaign is the identification of as many active chemotypes as possible for further evaluation. Often, however, the number of concentration response curves (e.g., IC 50 s or K i s) that can be collected following a primary screen is limited by practical constraints such as protein supply, screening workload, and so forth. One possible approach to this dilemma is to cluster the hits from the primary screen and sample only a few compounds from each cluster. This introduces the question as to how many compounds must be selected from a cluster to ensure that an active compound is identified, if it exists at all. This article seeks to address this question using a Monte Carlo simulation in which the dependence of the success of sampling is directly linked to screening data variability. Furthermore, the authors demonstrate that the use of replicated compounds in the screening collection can easily assess this variability and provide a priori guidance to the screener and chemist as to the extent of sampling required to maximize chemotype identification during the triage process. The individual steps of the Monte Carlo simulation provide insight into the correspondence between the percentage inhibition and eventual IC 50 curves. (Journal of Biomolecular Screening 2007:276-284) 
INTRODUCTION
T HE NUMBER OF COMPOUNDS tested in a typical highthroughput screening campaign has grown dramatically in the past decade due to advances in assay format, miniaturization, and data processing. 1 Nevertheless, the realities of assay time and cost still remain, particularly when progressing from a singlepoint determination into a full dose-response curve. To address these issues, an efficient mechanism for sampling the primary screening data is desirable, but any sampling strategy must accurately reflect the population of active chemotypes or else run the risk of missing hits. Further complicating this type of analysis is the variability inherent in biological assays, leading to the appearance of both false positives and negatives. Sufficient examples of each chemotype must be tested to ensure that no real actives are missed. The primary challenge in the selection process is achieving balance between sampling density and efficiency.
Two general approaches have been taken when selecting compound subsets: those based solely on the apparent biological activity from the primary assay and those that also incorporate some form of molecular information. The biologically based selection usually involves establishing a percentage inhibition cutoff, above which compounds are retested. Zhang and others 2 have carried out an extensive statistical analysis of this type of approach, incorporating the impact that noise has on the probability of missing hits at a given cutoff. Their simulations showed that depending on the quality of the assay, as established by Z factor, 3 and the desired activity level, reasonable hit rates were found by setting the cutoff 2σ s to 3σ s from the mean activity of the screen. This type of analysis coupled with pragmatic considerations is now commonly used when selecting compounds for progression. However, establishing a cutoff can lead to missed hits, as their activity may lie just below the threshold and will be ignored. More recently, Malo and others 4 reviewed several other approaches to normalization of biological results to select a suitable activity threshold. Nonetheless, because the chemical composition of the putative hits is not considered, it is not known whether the activity arises from a large cluster of very similar compounds or from a diverse set of chemotypes. If the goal is discovery of the largest number of synthetic starting points, the latter case is a much more efficient use of screening resources.
Recognizing the issues with simple cutoffs, many schemes have been devised that enhance the probability of finding hits by model building and mining the inactives. Glick and others 5, 6 and Rogers and others 7 have shown that Bayesian analysis can be used to enhance hit rates from high-throughput screens. The training set used for building the naïve Bayesian classifier is typically composed of actives retrieved from the primary screen and a subset of the inactive compounds. The model is then used to mine the remainder of the tested compounds with the goal of capturing any false negatives or to mine additional databases for potential actives. Although Bayesian classification with topological (ECFP 7 ) descriptors returns reasonable hit rates 5,7 even in the context of a noisy screen, it becomes less effective if the compounds being mined are not similar to those in the training set. 5 In a recent report, Glick and others have extended this analysis to include support vector machines and recursive partitioning. 6 The 3 methods tolerated noise both as false positives and false negatives, but support vector machines emerged as the best performing method. Although these model-building strategies certainly have utility for finding hits that expand the structure-activity relationship around a chemotype already deemed as active, they may not be the most effective means of sampling the landscape of active chemotypes within the screening set. An alternative to model building is clustering a set of actives by some representation of their chemical structure. Compound sets have been partitioned using BCUTs, 8 reduced graphs, 9 fingerprints, 10 maximum common substructures, 11 and scaffolds, 12 with the object of organizing these sets in a chemically meaningful way. Layering activity data into the clusters allows the identification of chemical regions enriched with actives and those scaffolds that are more highly represented. 12 The number of compounds selected for retest is then reduced by sampling clusters from this larger compound set. This has the potential for more efficiently retrieving distinct chemotypes and addresses the issue of overtesting a single chemical class, but its effectiveness is highly dependent on how representative compounds are picked from the clusters. One common strategy is simply selecting the most active compound from each cluster. By sampling limited compounds from clusters, a more relaxed activity cutoff can be applied to the primary screening data, potentially capturing compounds with primary activity data just below an artificially determined selection threshold. For assays with little variability and clusters containing highly active compounds, the probability is good that chemotypes will not be missed. However, selection of a single compound from a cluster containing a set of moderately active compounds could potentially lead to missed chemotypes. For example, if the most potent compound in the cluster was a false positive and failed on retest, the entire cluster could be rejected and the chemotype dismissed. This risk is compounded as the variability in the assay increases. It is often quite difficult to know how deeply clusters must be sampled to ensure the largest number of hits are found without wasting retest slots. Selection of singletons also presents a problem as they represent clusters of one. Because that compound represents the entire cluster, one wants to be sure that they are truly inactive before discarding them.
The methodology presented here incorporates the variability of the screening data into selection of compounds from clusters. Our analysis takes advantage of the fact that many compound collections contain compounds that are chemically identical but spread throughout the screening deck. Comparing the activities of these duplicate entities reveals the variability within the entire screening process and alleviates the need to consider errors introduced by any 1 step. Analysis of screening data from several assay types and formats showed a range of variabilities. Three representatives were chosen that reflect common assay types and formats. The noise profiles derived from 3 screens were then overlaid onto a prototypical idealized 10,772 compound screening set, resulting in 3 sets of data with identical compounds but whose activities had been perturbed in a manner consistent with the observed variabilities. From these data sets, 2 direct comparisons could be made: the correlation between IC 50 s that would be observed on retest and the percentage inhibition from the primary screen, and the efficiency of chemotype retrieval from compound clusters at various sampling depths. As expected, the IC 50 correlation degrades substantially as the variability in the assay increases, reinforcing the danger of using only cutoffs based on the primary data as a criterion for compound selection. The results of the clustering exercise demonstrate that it is indeed an efficient mechanism for chemotype retrieval as long as noise is considered. In a well-behaved enzymatic assay, selection of the single most active compound from a cluster is often sufficient to capture the majority of the chemotypes, but this is certainly not the case for the more variable cell-based receptor assays.
MATERIALS AND METHODS

Assays
Three assays were chosen for use in this study: a soluble kinase assay, receptor kinase assay, and a G protein-coupled receptor (GPCR) assay. The assays were chosen to represent several of the broad categories of assay formats frequently encountered in highthroughput screening (HTS).
Protein kinase assays. The soluble protein kinase assay was screened using the fluorescence resonance energy transfer-based Z-Lyte assay (Invitrogen, Carlsbad, CA). The Z'LYTE assay platform (Invitrogen) is based on the differential protease sensitivity of phosphorylated and nonphosphorylated peptide substrate. Peptide is labeled with coumarin and fluorescein, and cleavage is monitored by measuring the ratio of emission at 445 nm (coumarin) and 520 nm (fluorescein). The assay was run in the presence of 5 µM adenosine triphosphate (ATP) in a standard 384-well format on a fully automated robotic system. For this assay, Z′ = 0.85 and the average signal-to-noise ratio was 35.
The receptor tyrosine kinase assay was run using LEADseeker scintillation proximity assay (SPA) beads. The peptide substrate was tagged with biotin. The kinase was allowed to phosphorylate its substrate in the presence of 0.1 µCi ATP tracer along with 10 µM ATP and added test compounds at 10 µM. The reactions were stopped by the addition of streptavidin-coated LEADseeker ® SPA beads (GE Healthcare, Buckinghamshire, UK) resuspended in 25 mM ATP and 500 mM EDTA. The beads were allowed to settle overnight before the plates were imaged using a LEADseeker ® Plate Imager (GE Healthcare) for 5 min. Percentage inhibition was calculated relative to the positive control. For the receptor kinase assay, Z′ = 0.71 and the average signal-to-noise ratio was 12.
SPA receptor binding assay. Cells in HEPES-buffered phenol red-free media were preincubated with wheat germ agglutinin-coated polystyrene LEADseeker ® beads by gentle stirring for 30 min at room temperature. Following incubation, the cellbead mixture was added to all wells (containing test compounds at 10 µM) using a Titertek ® (Huntsville, AL) multidrop. Immediately following cell/bead addition, the [ 125 I]-labeled ligand was added to all wells using a Titertek ® multidrop. Prior to imaging, plates were incubated at room temperature for approximately 6 h to allow the reaction to reach equilibrium as well as the LEADseeker ® beads to settle to the bottom of the plate. Plates were subsequently imaged on a LEADseeker ® for 5 min. Percentage inhibition was calculated relative to the positive control. For the GPCR SPA receptor binding assay, Z′ = 0.52 and the average signal-to-noise ratio was 9.
Calculation of HTS assay variability. Following the initial primary high-throughput screen, compounds that are present in multiple wells in the screening collection are identified by duplicated corporate registry number. The average and standard deviation of the single-point inhibition data are calculated for each multiple-plated screening compound. These results were binned by the average percentage inhibition, and the average standard deviation of all duplicated compounds within each bin is calculated. The bin sizes were roughly defined in 5% inhibition increments. However, in several cases, this was not possible as the number of observations in a particular bin became very small. In these cases, the bin size was manually made larger to obtain a reasonable number of samples to estimate the variability. The inhibition-dependent calculated variability for each assay is given in Table 1 .
Idealized IC 50 Data
The HTS screening results for 10,772 compounds in a pure enzymatic kinase assay were used as the baseline for this experiment. These compounds were screened for percentage inhibition (%I) at 10 µM in duplicate. These percentage inhibition data were used to calculate the corresponding idealized IC 50 s using the Logit equation [13] [14] [15] :
Consequently, a perfect sigmoidal relationship is assumed to exist between the measured percent inhibition at 10 µM and the idealized IC 50 .
The experimental screening data and structures represent a true structure-activity relationship. The structures were clustered using a group average clustering method with Daylight Fingerprints 16 and a Tanimoto similarity of 0.65. Each cluster is designated as an active cluster or an inactive cluster. Active clusters are clusters that contain at least 1 compound with an IC 50 (as calculated above) that is equal to or less than 10 µM. Inactive clusters are those that contain only compounds with IC 50 s greater than 10 µM. It is important to note that a chemotype as viewed by a chemist may be divided across several clusters, but it is important that a cluster contain 1 and only 1 chemotype.
Combining idealized data with assay variability
For the purposes of this experiment, these data are considered to be ideal, zero-noise, screening data. From this starting point, each percentage inhibition value is perturbed by adding variability commensurate with its activity to obtain an apparent %I:
where %I i is the ideal percentage inhibition of compound i, norm_rand is a normally distributed random number with mean of 0 and standard deviation of 1, and sdev[%I i ] is the standard deviation calculated for the duplicated screening compounds in the same activity bin as compound i. The variability is biased by 5% (0.05) to result in compounds appearing less active on average after the addition of noise. This factor was selected by visual inspection based on the observation that most highthroughput percentage inhibition versus full IC 50 curves in house show a slight rightward shift. We speculate that this shift is the result of lower than expected compound concentrations arising from low compound solubility that is frequently observed in the pharmaceutical industry.
Clustering. The idealized data were derived from an actual high-throughput screen run internally. Therefore, the data represent a real structure-activity relationship that is consistent with the active analogue principle. The structures associated with these data were retrieved as simplified molecular input line entry system (SMILES) from a database. The compounds were clustered with a group average clustering algorithm using Daylight Fingerprints with a Tanimoto similarity of 0.65, resulting in 1364 clusters containing at least 2 compounds and 2694 singletons.
Compound selection by sampling chemical clusters by biological activity. Compounds are selected by choosing up to N compounds with the highest apparent percentage inhibition from each cluster. The highest apparent percentage inhibition is evaluated in the context of the known assay variability to determine if the compound will meet the IC 50 threshold for activity. The compound is selected if the apparent percentage inhibition could indicate activity exceeding a target IC 50 . In this report, we will use 10 µM as the threshold activity for being considered a hit. As the data were generated at a concentration of 10 µM, a compound is selected if equation 3 is true:
If that compound was not active based on the ideal IC 50 , the next highest apparent percentage inhibition compound was selected, and so on up to N. Metrics are computed for the number and percentage of active clusters identified for N = 1, 2, 3, or 4. The addition of variability to the idealized HTS data is repeated 10,000 times for each value of N used in the compound selection stage. The average number of compounds sampled and the average percentage of active clusters retrieved for each value of N are reported in Table 2 . The selection procedure is summarized in Figure 1 . Results for selecting a single compound based on equation 3 but using several values for k are given in Table 3 . Compound selection by biological activity threshold. Compounds are selected by setting a single cutoff value for the percentage inhibition. The average number of compounds sampled and the average percentage of active clusters retrieved for each of the 4 cutoffs (30%, 40%, 50%, and 60% inhibition) are reported in Table 4 .
Compound selection by randomly sampling from chemical clusters. Compounds are selected by randomly selecting compounds from chemical clusters. The average number of compounds sampled and the average percentage of active clusters retrieved for sampling from 1 to 4 compounds randomly from each chemical cluster are reported in 
RESULTS AND DISCUSSION
Historically, a key metric for the success of HTS has been the total number of confirmed active compounds identified during a screening campaign. With this goal in mind, it is now commonplace to use a particular cutoff of activity in the primary assay to select compounds for more rigorous analysis such as concentration response experiments. More recently, we have been interested in the number of active chemotypes identified for exploration by chemistry. As there is typically an upper limit to the number of dose-response curves that can be generated, one logical method to maximize the number of active chemotypes identified is to sample across as many chemotypes as possible. Not obvious in this approach is how many examples of each chemotype need to be tested to ensure identification of an active series.
It seems logical that the degree of sampling required would be directly related to the assay variability. Therefore, we implemented a Monte Carlo simulation method that would assess the impact of variability on the success of sampling. For historical and process-related reasons, a large number of compounds in the corporate inventory have been placed on the screening plates used in HTS in multiple wells. We have sought to exploit this redundancy as a measure of the assay variability. Figure 2 shows the distribution of the standard deviations of the compounds plated multiple times in 3 assays of different formats. The median variability of the assays is largely consistent with what is intuitively expected based on assay format: The kinase binding assay is lowest in variability, and the GPCR cell-based SPA assay is highest. It is apparent from this figure that the variability of the screening data is not constant, which raises a number of important issues in hit identification. 4 Figure 3 shows the variability broken out as the average value in bins based on percentage inhibition. Viewed in this way, the variability is highly related to activity in a manner that can be viewed as a mixture of Gaussians.
It is not difficult to postulate causes for this activity-dependent variability. Although an inactive compound may appear active for reasons such as contaminants or assay interference, it is less susceptible to other issues such as liquid-handling errors, solvent evaporation, or limited compound solubility. Conversely, a highly active compound is also conceptually less susceptible to some noise sources such as minor concentration fluctuations due to liquid-handling errors and so forth. However, a compound with activity near 50% inhibition at the tested concentration will likely have large variability due to minor changes in assay conditions such as ligand or protein concentration, compound solubility, compound purity, and so on. Interestingly, the cell-based GPCR assay shows a slight shift in peak variability toward higher activity. The activity-based variability was used to perturb the primary screening data in a Monte Carlo simulation method to probe the effect of the variability on the identification of active clusters of compounds. Figure 1 shows a flow chart of the Monte Carlo simulation procedure. Figures 4 to 6 show snapshots of the idealized IC 50 compared to the perturbed primary screening data from a single iteration of the Monte Carlo simulations of the kinase, receptor kinase, and GPCR assays, respectively. Also shown in these figures is the relationship between the true percentage inhibition and the true IC 50 from the real assay results for the limited compounds that were progressed to full concentrationresponse curves. Visually, the plots of the simulated HTS data show significant similarity to the true relationship seen after hit confirmation. The effect of the variability was evaluated with 3 different selection methods. Table 2 shows the aggregate results for the number of active clusters identified for each of the assays used in the study depending on the number of compounds sampled from each cluster, with a value of k = 1 for equation 3. For the assay with the lowest variability, selecting only 1 or 2 compounds based on the percentage inhibition yields an encouraging active chemotype identification rate. For the GPCR assay, significantly more sampling is required to approach the 90% identification rate. Also shown in Table 2 is the result of selecting random compounds from the clusters as opposed to selecting by the highest apparent activity. Selecting based on the highest percentage inhibition data gives significantly improved (p < 0.01) results compared to random selection for the majority of cases. The exceptions are selecting either up to 3 or 4 compounds from each cluster in the GPCR assay. Table 3 shows the results for selecting a single compound from each cluster, depending on the value of k used in the selection rule (equation 3). Although increasing the value of k generally increases the number of active clusters identified, it also rapidly increases the total number of compounds considered for concentration response determinations. We feel that a value of k = 1 is a prudent choice, although other values can certainly be used depending on assay capacity or other factors.
In contrast to the results for selecting based on cluster, Table 4 shows the results using a more typical activity-based cutoff for selecting compounds. Surprisingly, a selection threshold as low as 30% inhibition recalls no more active clusters than selecting a single compound from each cluster, even though significantly more compounds are selected for assay. This implies that entire clusters of compounds with modest activity are often missed or found only with great effort when using a single activity cutoff.
CONCLUSIONS
Using data from three different assay formats, we have demonstrated that a simple Monte Carlo simulation can provide insight into what extent of cluster sampling is required to ensure identification of active classes of compounds based on HTS data. Furthermore, we have demonstrated that the quality of the percentage inhibition versus IC 50 relationship that eventually emerges in HTS can be forecast using an activity-dependent variability model. This mixture of Gaussian approaches can be applied prospectively using a collection of compounds that has been plated and screened multiple times in the screen to alert the discovery team as to the extent of cluster sampling necessary for their screen. Although the method was evaluated using data from only 3 formats, we expect the approach to be reasonably transferable to other assay systems.
It is worth noting that the method is dependent on the presence of duplicated compounds in the screening collection. Conceptually, a selection of control plates could be screened multiple times to recreate this effect. However, the method relies on the total assay variability being accounted for in the duplicated compounds. This variability arises from many factors, including compound purity, compound solubility, liquid handling, temperature fluctuations, protein activity, and so forth, which may be difficult to replicate across the activity range if the compound collection was specifically designed for nonredundancy.
Although we have focused on moving compounds from primary HTS data to concentration-response curves, the approach is applicable in principle to other workflows such as 2-or 3-point percentage inhibition measures. When the desired outcome from an HTS is the maximal number of active chemotypes for subsequent follow-up, this approach offers several advantages over the simple activity-based threshold that is the industry norm.
